You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCortisone acetate
Accession NumberDB01380
TypeSmall Molecule
GroupsApproved
DescriptionCortisone acetate is a steroid hormone that has both glucocoriticoid and mineral corticoid activities. Corticosteroids are used to provide relief for inflamed areas of the body. They lessen swelling, redness, itching, and allergic reactions. They are often used as part of the treatment for a number of different diseases, such as severe allergies or skin problems, asthma, or arthritis. Endogenous glucocorticoids and some synthetic corticoids have high affinity to the protein transcortin (also called CBG, corticosteroid-binding protein), whereas all of them bind albumin. Glucocorticoids also bind to the cytosolic glucocorticoid receptor.
Structure
Thumb
Synonyms
Cortisyl
Cortone acetate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cortisone Acetate Tab 25mgTablet25 mgOralValeant Canada Lp Valeant Canada S.E.C.1973-12-31Not applicableCanada
Cortone Sus 50mg/mlSuspension50 mgIntramuscularMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1951-12-311999-08-06Canada
Cortone Tab 25mgTablet25 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1954-12-312002-07-29Canada
Cortone Tab 5mgTablet5 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1951-12-312002-07-29Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cortisone AcetateTablet25 mg/1OralWest ward Pharmaceutical Corp1972-06-13Not applicableUs
Cortisone AcetateTablet25 mg/1OralGolden State Medical Supply, Inc.1972-06-13Not applicableUs
Cortisone AcetateTablet25 mg/1OralHikma Pharmaceutical2013-08-26Not applicableUs
Cortisone AcetateTablet25 mg/1OralWest Ward Pharmaceuticals Corp2013-08-22Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Cortone Acetate MSD
Brand mixturesNot Available
SaltsNot Available
Categories
UNII883WKN7W8X
CAS number50-04-4
WeightAverage: 402.4807
Monoisotopic: 402.204238692
Chemical FormulaC23H30O6
InChI KeyITRJWOMZKQRYTA-RFZYENFJSA-N
InChI
InChI=1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-17,20,28H,4-9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1
IUPAC Name
2-[(1S,2R,10S,11S,14R,15S)-14-hydroxy-2,15-dimethyl-5,17-dioxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl]-2-oxoethyl acetate
SMILES
[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Pharmacology
IndicationFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders.
Structured Indications
PharmacodynamicsAs a glucocorticoid agent, cortisone acetate changes genetic transcription levels causing varied metabolic effects and a modified immune response to varied stimuli. lucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.
Mechanism of actionCortisone acetate binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glucocorticoid receptorProteinyes
agonist
HumanP04150 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationCorticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Half lifeNot Available
ClearanceNot Available
ToxicitySide effects include inhibition of bone formation, suppression of calcium absorption, delayed wound healing and hyperglycemia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with 1,10-Phenanthroline.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Cortisone acetate.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Cortisone acetate.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Cortisone acetate.Withdrawn
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Cortisone acetate.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Cortisone acetate.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Cortisone acetate.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Cortisone acetate.Experimental
AldesleukinCortisone acetate may decrease the antineoplastic activities of Aldesleukin.Approved
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Cortisone acetate.Approved
ALT-110The risk or severity of adverse effects can be increased when Cortisone acetate is combined with ALT-110.Investigational
Aluminum hydroxideThe bioavailability of Cortisone acetate can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of Cortisone acetate can be decreased when combined with Aluminum phosphate.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Cortisone acetate.Approved
AmiodaroneThe metabolism of Cortisone acetate can be decreased when combined with Amiodarone.Approved, Investigational
Amphotericin BCortisone acetate may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Cortisone acetate.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Cortisone acetate.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Cortisone acetate.Approved, Investigational
AprepitantThe serum concentration of Cortisone acetate can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe metabolism of Cortisone acetate can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Cortisone acetate can be decreased when combined with Atomoxetine.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Cortisone acetate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Cortisone acetate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Cortisone acetate.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Cortisone acetate.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Cortisone acetate.Approved, Investigational
BazedoxifeneThe serum concentration of Cortisone acetate can be increased when it is combined with Bazedoxifene.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Cortisone acetate.Investigational
BendroflumethiazideCortisone acetate may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Cortisone acetate.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Cortisone acetate.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Cortisone acetate.Investigational
BexaroteneThe serum concentration of Cortisone acetate can be decreased when it is combined with Bexarotene.Approved, Investigational
Bismuth SubcitrateThe bioavailability of Cortisone acetate can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe metabolism of Cortisone acetate can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Cortisone acetate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Cortisone acetate can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Cortisone acetate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Cortisone acetate.Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Cortisone acetate.Withdrawn
BumetanideCortisone acetate may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Cortisone acetate.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Cortisone acetate can be decreased when combined with Calcium carbonate.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Cortisone acetate.Approved
CarbamazepineThe metabolism of Cortisone acetate can be increased when combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Cortisone acetate.Approved, Vet Approved, Withdrawn
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Cortisone acetate.Experimental
CDX-110The risk or severity of adverse effects can be increased when Cortisone acetate is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Cortisone acetate.Approved, Investigational
CeritinibThe serum concentration of Cortisone acetate can be increased when it is combined with Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Cortisone acetate.Approved, Vet Approved
ChlorothiazideCortisone acetate may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Cortisone acetate can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Cortisone acetate.Approved
ChlorthalidoneCortisone acetate may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Cortisone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Cortisone acetate.Experimental
CinoxacinThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe metabolism of Cortisone acetate can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Cortisone acetate can be decreased when combined with Clemastine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Cortisone acetate.Approved
ClotrimazoleThe metabolism of Cortisone acetate can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Cortisone acetate can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Cortisone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Cortisone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Cortisone acetate can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Cortisone acetate can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Cortisone acetate.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Coumaphos.Vet Approved
CrizotinibThe metabolism of Cortisone acetate can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Cortisone acetate.Investigational
CyclosporineThe metabolism of Cortisone acetate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Cortisone acetate.Investigational
DabrafenibThe serum concentration of Cortisone acetate can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe metabolism of Cortisone acetate can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Cortisone acetate can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Cortisone acetate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Cortisone acetate can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Demecarium.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Cortisone acetate.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Cortisone acetate.Investigational
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Cortisone acetate.Investigational
DexamethasoneThe serum concentration of Cortisone acetate can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DichlorvosThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Cortisone acetate.Approved, Vet Approved
DienestrolThe serum concentration of Cortisone acetate can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Cortisone acetate can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Cortisone acetate.Approved
DihydroergotamineThe metabolism of Cortisone acetate can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneCortisone acetate may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe metabolism of Cortisone acetate can be decreased when combined with Diltiazem.Approved
DonepezilThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Donepezil.Approved
DoxycyclineThe metabolism of Cortisone acetate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Cortisone acetate can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Cortisone acetate.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Cortisone acetate.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Cortisone acetate.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Cortisone acetate.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Cortisone acetate.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Edrophonium.Approved
EfavirenzThe serum concentration of Cortisone acetate can be decreased when it is combined with Efavirenz.Approved, Investigational
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Cortisone acetate.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Cortisone acetate can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Cortisone acetate.Approved
ErythromycinThe metabolism of Cortisone acetate can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Cortisone acetate can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Cortisone acetate can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Cortisone acetate can be increased when it is combined with Estrone.Approved
Etacrynic acidCortisone acetate may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Cortisone acetate.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Cortisone acetate can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Cortisone acetate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Cortisone acetate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Cortisone acetate.Approved, Investigational
EtravirineThe serum concentration of Cortisone acetate can be decreased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Cortisone acetate.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Cortisone acetate.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Cortisone acetate.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Cortisone acetate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Cortisone acetate.Approved
FenthionThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Fenthion.Vet Approved
FingolimodCortisone acetate may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Cortisone acetate.Approved, Withdrawn
FluconazoleThe metabolism of Cortisone acetate can be decreased when combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Cortisone acetate.Vet Approved
FluoxymesteroneCortisone acetate may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Cortisone acetate.Approved, Investigational
FluvoxamineThe metabolism of Cortisone acetate can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Cortisone acetate can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Cortisone acetate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Cortisone acetate can be increased when combined with Fosphenytoin.Approved
FurosemideCortisone acetate may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Cortisone acetate can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Cortisone acetate can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Cortisone acetate is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Ginkgo biloba.Approved, Nutraceutical
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Cortisone acetate.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Cortisone acetate.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Cortisone acetate.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Cortisone acetate.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Cortisone acetate.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Cortisone acetate.Approved
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Cortisone acetate.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Grepafloxacin.Withdrawn
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Cortisone acetate.Investigational
HexestrolThe serum concentration of Cortisone acetate can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Cortisone acetate.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Cortisone acetate.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cortisone acetate.Approved, Investigational
HydrochlorothiazideCortisone acetate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideCortisone acetate may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Cortisone acetate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Cortisone acetate.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Cortisone acetate.Approved
IdelalisibThe serum concentration of Cortisone acetate can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Cortisone acetate can be decreased when combined with Imatinib.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Cortisone acetate.Approved
IndapamideCortisone acetate may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Cortisone acetate can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Cortisone acetate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Cortisone acetate.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Cortisone acetate is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Cortisone acetate is combined with INGN 225.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Cortisone acetate.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Cortisone acetate.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Cortisone acetate.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Cortisone acetate.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Cortisone acetate.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Cortisone acetate.Approved
IsavuconazoniumThe metabolism of Cortisone acetate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Cortisone acetate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Cortisone acetate.Withdrawn
IsradipineThe metabolism of Cortisone acetate can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Cortisone acetate can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Cortisone acetate can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Cortisone acetate.Experimental
KetoconazoleThe metabolism of Cortisone acetate can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Cortisone acetate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Cortisone acetate.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Leflunomide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Levofloxacin.Approved, Investigational
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Cortisone acetate.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Cortisone acetate.Approved
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Cortisone acetate.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Lomefloxacin.Approved
LopinavirThe metabolism of Cortisone acetate can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Cortisone acetate.Approved
LovastatinThe metabolism of Cortisone acetate can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Cortisone acetate.Approved
LuliconazoleThe serum concentration of Cortisone acetate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Cortisone acetate can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Cortisone acetate.Approved, Investigational
MagaldrateThe bioavailability of Cortisone acetate can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Cortisone acetate can be decreased when combined with Magnesium carbonate.Approved
Magnesium hydroxideThe bioavailability of Cortisone acetate can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Cortisone acetate can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Cortisone acetate.Approved
Magnesium TrisilicateThe bioavailability of Cortisone acetate can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Cortisone acetate.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Cortisone acetate.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Cortisone acetate.Approved
MefloquineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Cortisone acetate.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Cortisone acetate.Approved
MestranolThe serum concentration of Cortisone acetate can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Cortisone acetate.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Cortisone acetate.Approved
MethallenestrilThe serum concentration of Cortisone acetate can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideCortisone acetate may increase the hypokalemic activities of Methyclothiazide.Approved
MethyltestosteroneCortisone acetate may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazoneCortisone acetate may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Cortisone acetate can be decreased when used in combination with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Cortisone acetate.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Cortisone acetate.Approved
MinaprineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Minaprine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Cortisone acetate.Approved, Investigational
MitotaneThe serum concentration of Cortisone acetate can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Cortisone acetate.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Cortisone acetate.Investigational
ModafinilThe serum concentration of Cortisone acetate can be decreased when it is combined with Modafinil.Approved, Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Cortisone acetate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Cortisone acetate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Cortisone acetate.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Cortisone acetate.Investigational
NafcillinThe serum concentration of Cortisone acetate can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Cortisone acetate.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Cortisone acetate.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Natalizumab.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Cortisone acetate.Approved, Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Cortisone acetate.Investigational
NefazodoneThe metabolism of Cortisone acetate can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Cortisone acetate can be decreased when combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Cortisone acetate.Approved
NetupitantThe serum concentration of Cortisone acetate can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Cortisone acetate can be increased when combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Cortisone acetate.Approved
NilotinibThe metabolism of Cortisone acetate can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Cortisone acetate.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Cortisone acetate.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Ofloxacin.Approved
OlaparibThe metabolism of Cortisone acetate can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Cortisone acetate.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Cortisone acetate.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Cortisone acetate.Vet Approved
OsimertinibThe serum concentration of Cortisone acetate can be increased when it is combined with Osimertinib.Approved
OxandroloneCortisone acetate may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Cortisone acetate.Approved
OxymetholoneCortisone acetate may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Cortisone acetate.Withdrawn
PalbociclibThe serum concentration of Cortisone acetate can be increased when it is combined with Palbociclib.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Cortisone acetate.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Pefloxacin.Approved
PentobarbitalThe metabolism of Cortisone acetate can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Cortisone acetate.Approved, Withdrawn
PhenobarbitalThe metabolism of Cortisone acetate can be increased when combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Cortisone acetate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Cortisone acetate.Approved, Vet Approved
PhenytoinThe metabolism of Cortisone acetate can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cortisone acetate.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Cortisone acetate.Approved, Investigational
PiretanideCortisone acetate may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Cortisone acetate.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Cortisone acetate.Approved, Investigational
Polyestradiol phosphateThe serum concentration of Cortisone acetate can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideCortisone acetate may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe metabolism of Cortisone acetate can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Cortisone acetate.Approved, Investigational
PrimidoneThe metabolism of Cortisone acetate can be increased when combined with Primidone.Approved, Vet Approved
PromestrieneThe serum concentration of Cortisone acetate can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Cortisone acetate.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Cortisone acetate.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Cortisone acetate can be increased when it is combined with Quinestrol.Approved
QuinethazoneCortisone acetate may increase the hypokalemic activities of Quinethazone.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Cortisone acetate.Approved
RanolazineThe metabolism of Cortisone acetate can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Cortisone acetate.Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Cortisone acetate.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Cortisone acetate.Experimental, Investigational
RifabutinThe metabolism of Cortisone acetate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Cortisone acetate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Cortisone acetate can be increased when combined with Rifapentine.Approved
RitonavirThe metabolism of Cortisone acetate can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Cortisone acetate.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Cortisone acetate.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Cortisone acetate.Approved, Investigational
RosoxacinThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Rosoxacin.Approved
S EquolThe serum concentration of Cortisone acetate can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Cortisone acetate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Cortisone acetate.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Cortisone acetate.Approved
SaquinavirThe metabolism of Cortisone acetate can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Cortisone acetate.Approved
SecoisolariciresinolThe serum concentration of Cortisone acetate can be increased when it is combined with Secoisolariciresinol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Cortisone acetate.Approved, Investigational
SildenafilThe metabolism of Cortisone acetate can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Cortisone acetate can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Cortisone acetate can be increased when it is combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cortisone acetate.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Cortisone acetate.Approved, Investigational
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Cortisone acetate.Approved
Somatropin recombinantThe therapeutic efficacy of Cortisone acetate can be decreased when used in combination with Somatropin recombinant.Approved, Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Cortisone acetate is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Cortisone acetate.Investigational
St. John's WortThe serum concentration of Cortisone acetate can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololCortisone acetate may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Cortisone acetate can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Cortisone acetate.Approved
SulfisoxazoleThe metabolism of Cortisone acetate can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Cortisone acetate.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Cortisone acetate.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Cortisone acetate.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Cortisone acetate can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Cortisone acetate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Cortisone acetate.Approved, Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Cortisone acetate.Approved
TelithromycinThe metabolism of Cortisone acetate can be decreased when combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Temafloxacin.Withdrawn
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Cortisone acetate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Cortisone acetate.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Cortisone acetate.Approved
TesamorelinThe serum concentration of the active metabolites of Cortisone acetate can be reduced when Cortisone acetate is used in combination with Tesamorelin resulting in a loss in efficacy.Approved, Investigational
TestosteroneCortisone acetate may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Cortisone acetate is combined with TG4010.Investigational
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Cortisone acetate.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Cortisone acetate.Approved
TiboloneThe serum concentration of Cortisone acetate can be increased when it is combined with Tibolone.Approved
TiclopidineThe metabolism of Cortisone acetate can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Cortisone acetate.Investigational
TocilizumabThe serum concentration of Cortisone acetate can be decreased when it is combined with Tocilizumab.Approved
TofacitinibCortisone acetate may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Cortisone acetate.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Cortisone acetate.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Cortisone acetate.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Cortisone acetate.Approved
TorasemideCortisone acetate may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Cortisone acetate.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Cortisone acetate.Approved, Investigational
TrichlorfonThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Trichlorfon.Vet Approved
TrichlormethiazideCortisone acetate may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Cortisone acetate.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Cortisone acetate.Withdrawn
TrovafloxacinThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Cortisone acetate.Investigational, Withdrawn
VenlafaxineThe metabolism of Cortisone acetate can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Cortisone acetate can be decreased when combined with Verapamil.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Cortisone acetate.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Cortisone acetate.Approved, Investigational
VoriconazoleThe metabolism of Cortisone acetate can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinCortisone acetate may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Cortisone acetate.Approved
ZeranolThe serum concentration of Cortisone acetate can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Cortisone acetate.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Cortisone acetate can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Cortisone acetate.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Reichstein,T.; US. Patent 2,403,683; July 9, 1946.
Gallagher,T.F.; US. Patent 2,447,325; August 17,1948; assigned to Research Corporation.
Sarett, L.H.; U.S. Patent 2,541,104; February 13, 1951; assigned to Merck & Co., Inc.

General ReferencesNot Available
External Links
ATC CodesH02AB10S01BA03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.983
Blood Brain Barrier+0.9851
Caco-2 permeable-0.6606
P-glycoprotein substrateSubstrate0.7382
P-glycoprotein inhibitor IInhibitor0.7341
P-glycoprotein inhibitor IIInhibitor0.5925
Renal organic cation transporterNon-inhibitor0.7452
CYP450 2C9 substrateNon-substrate0.8551
CYP450 2D6 substrateNon-substrate0.9294
CYP450 3A4 substrateSubstrate0.7841
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9556
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8588
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9246
Ames testNon AMES toxic0.9409
CarcinogenicityNon-carcinogens0.9551
BiodegradationNot ready biodegradable0.9354
Rat acute toxicity2.1280 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9599
hERG inhibition (predictor II)Non-inhibitor0.6638
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral25 mg/1
TabletOral25 mg
SuspensionIntramuscular50 mg
TabletOral5 mg
Prices
Unit descriptionCostUnit
Cortisone acetate powder24.18USD g
Cortisone Acetate 25 mg Tablet0.47USD tablet
Cortisone 25 mg tablet0.46USD tablet
Cortaid 1% cream0.21USD g
CVS Pharmacy cortisone 1% cream0.18USD g
CVS Pharmacy anti-itch 1% cream0.13USD g
Hydrocortisone 0.5% cream0.11USD g
Medi-cortisone 1% cream0.1USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point227-229Reichstein,T.; US. Patent 2,403,683; July 9, 1946. Gallagher,T.F.; US. Patent 2,447,325; August 17,1948; assigned to Research Corporation. Sarett, L.H.; U.S. Patent 2,541,104; February 13, 1951; assigned to Merck & Co., Inc.
water solubility20 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.10HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0278 mg/mLALOGPS
logP2.35ALOGPS
logP2.1ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)12.6ChemAxon
pKa (Strongest Basic)-3.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area97.74 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity105.63 m3·mol-1ChemAxon
Polarizability43.25 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassPregnane steroids
Direct ParentGluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Substituents
  • Progestogin-skeleton
  • 20-oxosteroid
  • 17-hydroxysteroid
  • Oxosteroid
  • 11-oxosteroid
  • Hydroxysteroid
  • 3-oxosteroid
  • 3-oxo-delta-4-steroid
  • Delta-4-steroid
  • Alpha-acyloxy ketone
  • Cyclohexanone
  • Acetate salt
  • Tertiary alcohol
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Ketone
  • Carboxylic acid ester
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
  • C21 steroids (gluco/mineralocorticoids, progestogens) and derivatives (C08173 )
  • C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030120 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21. [PubMed:16891588 ]
  2. Rautanen A, Eriksson JG, Kere J, Andersson S, Osmond C, Tienari P, Sairanen H, Barker DJ, Phillips DI, Forsen T, Kajantie E: Associations of body size at birth with late-life cortisol concentrations and glucose tolerance are modified by haplotypes of the glucocorticoid receptor gene. J Clin Endocrinol Metab. 2006 Nov;91(11):4544-51. Epub 2006 Aug 8. [PubMed:16895953 ]
  3. Hammer F, Stewart PM: Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):337-53. [PubMed:16980198 ]
  4. Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12. [PubMed:17038445 ]
  5. Sher L: Combined dexamethasone suppression-corticotropin-releasing hormone stimulation test in studies of depression, alcoholism, and suicidal behavior. ScientificWorldJournal. 2006 Oct 31;6:1398-404. [PubMed:17086345 ]
  6. Schlechte JA, Ginsberg BH, Sherman BM: Regulation of the glucocorticoid receptor in human lymphocytes. J Steroid Biochem. 1982 Jan;16(1):69-74. [PubMed:7062741 ]
  7. Schlechte JA, Sherman BM: Decreased glucocorticoid receptor binding in adrenal insufficiency. J Clin Endocrinol Metab. 1982 Jan;54(1):145-9. [PubMed:7054210 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on July 06, 2007 14:32 / Updated on August 19, 2016 10:26